Drug Pricing In The Next Senate: Incoming Finance Chair Grassley Outlines Priorities
A key figure in determining what Rx bills advance in Congress, Grassley recently expressed interest in working with House Democrats in a floor speech on his drug pricing priorities.
You may also be interested in...
HHS proposal to eliminate the “safe harbor” that allows for prescription drug rebates took a long time to clear White House review. Its release sends a clear message that US HHS Secretary Azar wants to lead the drug pricing debate in 2019.
Senate Finance Committee's Jan. 29 witnesses will include economists, a patient advocate and “others,” to be announced in the coming days, panel says.
Roche, through Genentech, returns to the PhRMA fold after leaving the trade group in 2009; Gilead is a first-time member; both are retaining their BIO memberships as well.